SI3003383T1 - Trdni sestavek za oralno dajanje, ki vsebuje ibandronsko kislino ali njeno farmacevtsko sprejemljivo sol, in vitamin D - Google Patents

Trdni sestavek za oralno dajanje, ki vsebuje ibandronsko kislino ali njeno farmacevtsko sprejemljivo sol, in vitamin D

Info

Publication number
SI3003383T1
SI3003383T1 SI201431025T SI201431025T SI3003383T1 SI 3003383 T1 SI3003383 T1 SI 3003383T1 SI 201431025 T SI201431025 T SI 201431025T SI 201431025 T SI201431025 T SI 201431025T SI 3003383 T1 SI3003383 T1 SI 3003383T1
Authority
SI
Slovenia
Prior art keywords
vitamin
pharmaceutically acceptable
acceptable salt
oral administration
solid composition
Prior art date
Application number
SI201431025T
Other languages
English (en)
Inventor
Serra Joao Pedro Silva
Isabel Maria Soares
Original Assignee
Tecnimede Sociedade Tecnico-Medicinal S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50943510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3003383(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tecnimede Sociedade Tecnico-Medicinal S.A. filed Critical Tecnimede Sociedade Tecnico-Medicinal S.A.
Publication of SI3003383T1 publication Critical patent/SI3003383T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201431025T 2013-05-31 2014-05-30 Trdni sestavek za oralno dajanje, ki vsebuje ibandronsko kislino ali njeno farmacevtsko sprejemljivo sol, in vitamin D SI3003383T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT106978A PT106978A (pt) 2013-05-31 2013-05-31 Composição sólida oral contendo ácido ibandrónico e vitamina d
EP14730606.2A EP3003383B1 (en) 2013-05-31 2014-05-30 Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d
PCT/PT2014/000036 WO2014193255A1 (en) 2013-05-31 2014-05-30 Solid composition for oral administration containing ibandronic acid or a pharmaceutically acceptable salt thereof and vitamin d

Publications (1)

Publication Number Publication Date
SI3003383T1 true SI3003383T1 (sl) 2019-03-29

Family

ID=50943510

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201431025T SI3003383T1 (sl) 2013-05-31 2014-05-30 Trdni sestavek za oralno dajanje, ki vsebuje ibandronsko kislino ali njeno farmacevtsko sprejemljivo sol, in vitamin D

Country Status (16)

Country Link
US (1) US20160106766A1 (sl)
EP (1) EP3003383B1 (sl)
BR (1) BR112015029897A2 (sl)
CL (1) CL2015003468A1 (sl)
DK (1) DK3003383T3 (sl)
ES (1) ES2705074T3 (sl)
HU (1) HUE040666T2 (sl)
LT (1) LT3003383T (sl)
MA (1) MA38688B1 (sl)
MX (1) MX364680B (sl)
PL (1) PL3003383T3 (sl)
PT (2) PT106978A (sl)
RS (1) RS58133B1 (sl)
SI (1) SI3003383T1 (sl)
TR (1) TR201821157T4 (sl)
WO (1) WO2014193255A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3095447T3 (da) 2006-02-03 2022-01-31 Opko Renal Llc Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
CN104257667B (zh) 2007-04-25 2019-06-04 欧普科Ip 控股Ii 有限公司 治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
EP3193925A2 (en) 2014-08-07 2017-07-26 OPKO Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin d
KR20230054752A (ko) 2016-03-28 2023-04-25 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
JP2005531532A (ja) 2002-04-05 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド アレンドロナートおよびビタミンｄ製剤を用いる骨吸収阻害法
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
US20080139514A1 (en) * 2006-11-29 2008-06-12 Subhash Pandurang Gore Diphosphonic acid pharmaceutical compositions
US20100179110A1 (en) * 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
EP1972341A1 (en) 2007-03-23 2008-09-24 Novartis AG Pharmaceutical compositions comprising a bisphosphonate and vitamin D
WO2010075537A1 (en) * 2008-12-23 2010-07-01 Teva Pharmaceutical Industries Ltd. Formulations comprising vitamin d or derivatives thereof
EP2416756A2 (en) * 2009-04-10 2012-02-15 Mahmut Bilgic Stable pharmaceutical compositions with high bioavailibility
IT1396937B1 (it) * 2009-11-26 2012-12-20 Bruzzese Formulazioni di bisfosfonati e vitamina d idonee alla somministrazione intermittente per via intramuscolare e sottocutanea
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
GB2502032B (en) * 2011-03-02 2015-03-04 D3 Pharma Ltd Stable Vitamin D3 Composition

Also Published As

Publication number Publication date
MX364680B (es) 2019-05-03
TR201821157T4 (tr) 2019-02-21
PL3003383T3 (pl) 2019-04-30
DK3003383T3 (en) 2019-01-28
MA38688B1 (fr) 2018-08-31
MA38688A1 (fr) 2017-07-31
RS58133B1 (sr) 2019-02-28
CL2015003468A1 (es) 2016-07-22
LT3003383T (lt) 2019-03-12
EP3003383A1 (en) 2016-04-13
US20160106766A1 (en) 2016-04-21
BR112015029897A2 (pt) 2017-07-25
PT106978A (pt) 2014-12-02
PT3003383T (pt) 2019-01-16
ES2705074T3 (es) 2019-03-21
EP3003383B1 (en) 2018-10-03
MX2015016497A (es) 2016-09-08
HUE040666T2 (hu) 2019-08-28
WO2014193255A1 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
HUE040666T2 (hu) Ibandronsavat vagy gyógyászatilag elfogadható sóját és D vitamint tartalmazó, orális beadásra alkalmas szilárd kompozíció
HK1223935A1 (zh) 無定形萊特莫韋及其用於口服施用的固體藥物製劑
HK1218884A1 (zh) 用於在口腔中釋放至少種活性藥物成分的固體藥物劑型
HK1200337A1 (en) Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
EP3020417A4 (en) Pharmaceutical composition for respiratory administration
HK1245646A1 (zh) 口服給藥用醫藥組合物
IL239958A (en) A chewable oral preparation and process for preparing it
HK1232144A1 (zh) 經口給藥用醫藥組合物
EP2979698A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
EP3082783A4 (en) Stable oral pharmaceutical composition
HUE044668T2 (hu) Dózisformák hatóanyagok orális beadásához